Amphomycin is a lipopeptide antibiotic produced by Streptomycetes and Actinoplanes, initially isolated by researchers at Bristol-Myers in 1953 from Streptomyces canus. Amphomycin was marketed as a complex of closely related analogs in the 1950s and 1960s. Structure elucidation was not completed until 2000. Amphomycin is closely related to a number of "lost" antibiotics, aspartocin, crystallomycin, glumamycin, friulimicin, laspartocin, tsushimycin and zaomycin. Interest in Amphomycin was re-awakened with the discovery of friulimicin activity against antibiotic resistant strains. It can be studied as a scaffold for structural modifications.
Amphomycin is soluble in ethanol, methanol, DMF and DMSO.
